For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
A Randomized Trial of Low-Animal-Protein or High-Fiber Diets for Secondary Prevention of Calcium NephrolithiasisDussol B.a, b · Iovanna C.b · Rotily M.c · Morange S.b · Leonetti F.e · Dupuy P.b · Vazi A.b · Saveanu A.a · Loundou A.d · Berland Y.a, b
aCentre de Néphrologie et de Transplantation Rénale, Assistance Publique, Hôpitaux de Marseille, Université Aix-Marseille II, bCentre d’Investigations Cliniques, Assistance Publique, Hôpitaux de Marseille et INSERM, cORS PACA-INSERM U379, et dUnité d’Aide Méthodologique, Université Aix-Marseille II, Marseille, et eService de Néphrologie, CHG Saint Brieuc, Saint-Brieuc, France
Background: The purpose of this trial was to evaluate the efficacy of a low-animal-protein diet (LAPD) or a high-fiber diet (HFD) for the prevention of calcium nephrolithiasis recurrence. Methods: We conducted a 4-year randomized trial comparing the effect of 2 diets in 175 idiopathic calcium stone formers. Fifty-five were assigned to a LAPD (<13% of total energy derived from protein), 60 were assigned to a HFD (>25 g/day fiber) and 60 were placed on a normal diet (control group). The primary outcome measure was the time to the first recurrence of calcium nephrolithiasis. Daily urine compositions were analyzed at baseline, at month 4 (M4), M12, M24, M36 and M48. Results: Seventy-three patients completed the trial (23 in the LAPD group, 27 in the HFD group and 23 in the control group). Recurrence was 48% (11/23) in the LAPD group, 63% (17/27) in the HFD group and 48% (11/23) in the control group (p = not significant). During follow-up, urinary calcium levels and other urine parameters did not change significantly in the 3 groups, except for a significant decrease in 24-hour urinary sulfate in the LAPD group. Conclusions: In idiopathic calcium stone formers, neither a LAPD nor a HFD appeared to provide protection against recurrence.
© 2008 S. Karger AG, Basel